Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

August 28th, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>


The State of Genomics and Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

Public Health Genomics (PHG) at the National Cancer Institute promotes the integration of genomics and personalized medicine into public health cancer research, policy, and control to reduce the burden of cancer in the United States and around the world.

Hybrid GenConnect Purpose in Genomic Science is to Draw from Organizational Theory and existing body of work about science. Hybrid seeks to operationalize a Model to represent empirical evidence that draws on Quanative mapping of Breast
Cancer

18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women.
GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Hybrid GenConnect will Reduce Breast Cancer by 5 percentage points by 2014

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

July 14, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

Gastric bypass procedures (GBP) is operations that divides the stomach into a small upper pouch and a much larger lower "remnant" pouch and then re-arranges the small intestine to allow both pouches to stay connected to it. Surgeons have developed several different ways to reconnect the intestine, thus leading to several different GBP names. Any GBP leads to a marked reduction in the functional volume of the stomach, accompanied by an altered physiological and physical response to food
Hybrid GenConnect Inc estimated 908,000 people in the U.S. had gastric bypass, gastric banding , or some other form of bariatric.


Candidates for bariatric surgery include those who are morbidly obese, which for most people means being 100 or more pounds overweight or having a body mass index (BMI) of 40 or more.

A 5-foot, 8 -inch person who weighs 250 or more would be considered morbidly obese, as would someone who is 6 feet tall and weighs at least 295 pounds.

Hybrid GenConnect Inc and others studied 900,000 adults followed for 16 years, Calle, et al, found the death rate from cancer was increased by 52 percent in men and 62 percent in women when the initial BMI was 40 or more. Cancers of the esophagus, colon and rectum, liver, gall bladder, pancreas, kidney, non-Hodgkins lymphoma and multiple myeloma were increased in both men and women. Stomach and prostate cancer was increased in men. Breast, uterus, cervix and ovary cancer were increased in women. They estimated, on the basis of this study, that overweight and obesity could account for 14 percent of all cancer deaths in the United States in men and 20 percent in women.
The newly reported study included 1,035 morbidly obese patients who underwent bariatric surgery between 1986 and 2002 and 5,746 patients matched for age, gender, and duration of morbid obesity who did not have surgery.

During five years of follow-up, 21 (2%) surgically treated patients were diagnosed with cancer, compared to 487 (8.5%) of nonsurgically treated patients.

The bariatric surgery patients had an 85% lower incidence of breast cancer, a 70% lower incidence of colon and pancreatic cancer, a 50% lower incidence of non-Hodgkin's lymphoma, and a 60% lower incidence of skin cancer
Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find P53,P63,BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid GenConnect breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.

Black Women #1 Concern The hTERT Gene for Breast Cancer

June 22, 2011 By Robert Graham Reporting Park Plaza Medical Center in Houston Texas is looking at the hTERT Gene for Breast Cancer -----< Business--Wire>

Hybrid GenConnect Genomics Project at its new location at Park Plaza Medical Center in Houston Texas is looking at the hTERT Gene for Breast Cancer


hTERT (human telomerase reverse transcriptase) gene is the rate-limiting determinant of telomerase reactivation. The GenConnect study aims to quantitatively measure the expression of hTERT mRNA in human breast cancer, adjacent non-cancerous tissue (ANCT) and benign breast lesions, examine the association between hTERT and the clinicopathological characteristics of the cancer specimens and to explore the relationship between c-Myc and hTERT expressions. GenConnect extracted RNA from 49 breast carcinomas, 46 matched ANCT, and eight fibroadenomas. hTERT and c-Myc mRNA expressions were estimated by reverse transcriptase-PCR (RT-PCR) and Taqman methodology.


Hybrid GenConnect Genomics R&D shows that Breast cancer is the second leading cause of cancer death among American women. African American (AA) women are more likely to die from breast cancer than Caucasian (CAU) women revealing a clear disparity between AA women and women of other ethnicities. Genetic Data collected by Hybrid GenConnect and others reveal that although AA women show a lower incidence of breast cancer than CAU women, AA women tend to have larger, more aggressive tumors, and have a lower 5-year survival rate than their CAU, Hispanic, Asian and Native American counterparts. Importantly, AA women are more likely to die from breast cancer than any other ethnic group. While socio-economic, cultural and environmental factors are thought to contribute to these disparities, little is known as to whether biological differences may exist between CAU and AA women with breast cancer. To determine whether biological factors contribute to differential cellular responses in AA and CAU women, triple-negative breast cancer cells from AA and CAU women were cultured and treated with dietary bioactive compounds (−)- epigallocatechin-3-gallate (EGCG) and sulforaphane (SFN), both of which are known to actively repress breast cancer. Preliminary findings reveal differential RNA expression of the human telomerase reverse transcriptase gene (hTERT) in AA and CAU cells. Additionally, AA cells showed differences in responsiveness to ECGG and SFN treatments when compared to CAU cells. These results support
the hypothesis that biological differences may contribute to the disparity among AA and CAU women with breast cancer.

Given Treatment of A431 cells with green tea polyphenols and its components, epigallocatechin-3-gallate, epigallocatechin, and epicatechin-3-gallate, resulted in the formation of internucleosomal DNA fragments, characteristic of apoptosis. Treatment with epigallocatechin- 3-gallate also resulted in apoptosis in HaCaT, L5178Y, and DU145 cells, but not in NHEK. Confocal microscopy and flow cytometry confirmed the findings. The DNA cell cycle analysis showed that in A431 cells, epigallocatechin- 3-gallate treatment resulted in arrest in the G0−G1 phase of the cell cycle and a dose-dependent apoptosis. Conclusions: Green tea may protect against cancer by causing cell cycle arrest and inducing apoptosis. It needs to be evaluated in human trials.
Given Treatment sulforaphane, a natural component of broccoli and other brassica vegetables, reduces the growth of breast cancer stem cells and impairs their viability. The effects of sulforaphane on breast cancer stem cells in the laboratory were evaluated using various methods. Sulforaphane was found to reduce the stem cell population (as measured by a stem cell marker) by 65% to 80% in human breast cancer cells. In an additional experiment, mice were implanted with breast cancer xenografts and the tumors were treated directly with sulforaphane. The impact of the treatment was assessed in part by measuring tumor growth upon cell reimplantation into a second group of mice. Daily injection with 50 mg/kg sulforaphane for two weeks was found to reduce the number of stem cells by more than 50% in the xenograft tumors. Sulforaphane's ability to eliminate breast cancer stem cells appeared to prevent tumor growth after the reimplantation of primary tumor cells into the second group of mice. The authors conclude that sulforaphane inhibits breast cancer stem cells and that the findings warrant further clinical evaluation.

Breast Cancer Survivors Families Epidemiology & Genomics Can Stop Cancer in its Tracks

June 14, 2011 By Robert Graham Reporting from University of Texas Medical Center Houston -----< Business--Wire>


Breast Cancer Survivors Families Epidemiology & Genomics can Stop Cancer in its Tracks


Epidemiology: The study of the patterns, causes, and control of disease in groups of people.
Genomics: The study of the complete genetic material, including genes and their functions, of an organism.

Cancer epidemiology seeks to understand the biological, environmental and social risk factors of cancer with the goal of guiding efforts at prevention and

treatment. Examples of cancer research by Hybrid GenConnect researchers includes evaluation of the efficacy of chemoprevention to prevent secondary tumors, the association between racial disparities in breast cancer survival, the relationship between insulin resistance and breast cancer incidence, and the identification of genetic cancer susceptibility risk factors
Although genetic influences on breast cancer risk have been recognized for many years, high-throughput genotyping involving genome-wide association studies has transformed research on the etiology of cancer and many other diseases. This technological breakthrough and the agnostic search for signals have opened up avenues for research that otherwise would have remained hidden for years. For instance, we may not know why a variant in a "gene desert" (a stretch of DNA devoid of protein-encoding genes) is consistently associated with risks of breast, prostate, and several other cancers, but we must infer that an important model of genes and cancer induction needs major revision
Hybrid GenConnect Inc Genetic research experts within the Breast Cancer Division are investigating the role of genes in such diseases as Alzheimer’s disease, cardiovascular disease, diabetes, hypertension, obesity, respiratory diseases and vision disorders. Understanding the genetics of these diseases involves locating and characterizing the underlying genes, characterizing the extent and utility of DNA variation within and among populations, determining how patterns of DNA variation evolved in time and space, and establishing the impact of gene variation on the health of individuals, families and populations. Hybrid researchers are also responsible for developing computational and bioinformatic approaches and resources for investigating the genetic etiology of disease.
Hybrid GenConnect Research in Genomic Epidemiology (CHARGE), which is led by a team at Park Plaza Hospital, hope that pooling their combined resources will help speed the process of defining all the genetic factors involved in Breast Cancer. “Our first efforts will be to bring together all the data from the different groups so that they can be analyzed,” for Drug Safety/Epidemiology.
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15oC to 27oC, bulk sample storage at 15oC to 27oC, walk-in cold sample storage -20oC to 5oC, ultra-low temperature storage -70C to -80C, and -190oC vapor phase liquid nitrogen. In addition, Hybrid GenConnect maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About Hybrid GenConnect Inc,.
For 23 years, Hybrid Medical eNotebook Inc Core Competency are Biotech Engineering, Software Engineers, and Enterprise Networking. At Hybrid Medical we pride ourselves on our Boutique Relationship with our Private Sector and Public Sector Clients. This methodology allows us to be able to offer our Clients “End to End” Solutions to their Enterprise Services. We have done extensive Research in Service Oriented Architecture (S.O.A) and Enterprise Service Bus (ESB) and we feel that our Strategies and your Strategies create valuable Synergies. Let's investigate the Possibilities for Synergies between our Company and yours.
HMA Inc we provide Network Services Contracts that include: design, installation and management of wide area networks and local area networks; enterprise server services that include anti-virus and content filters; BlackBerry support; patch support; technical helpdesk support including network hardware and software maintenance; desktop hardware/software installation and integration; application development; systems integration; Java/Oracle and legacy database development and maintenance; and citywide closed-circuit television services.>
HMA Inc comprehensive data protection strategy can save your company time. Our Process of backing up files, applications, databases, email and networked devicesis protected to ensure business continuity and compliance. When your business matures and grows, the volume of data increases and newer and more complex data retention requirements are introduced you are covered by hmnotebook.com Cloud Data Center (MCDC)™

Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

May 31, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----<

Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

Houston (May 26, 2011) – Hybrid GenConnect, the premier global provider of comprehensive sample management solutions, announced today that it has opened its new state-of-the-art biorepository facility in Houston. The 4,000-square-foot facility is part of the company’s strategic growth plan, and represents a Major investment by Hybrid GenConnect.
Strategically placed near the second largest Cities in the United States, the new facility is dedicated to the preparation, storage and cold-chain transport of human biological samples for a wide variety of customers, including academic centers, contract research organizations, donor programs and biotechnology companies. Within the facility, Hybrid GenConnect is continuing to employ a growing number of sample management experts, making it one of the largest and mohttp://www.blogger.com/img/blank.gifst technology-driven biorepositories in the world.
“Hybrid GenConnect is committed to its investment in comprehensive sample management solutions, and this new facility provides the company with the infrastructure needed to support our continued growth and services expansion,” said Rose Conrad, CEO of Hybrid GenConnect.
The facility expansion has provided Hybrid GenConnect the ability to offer sample preparation services, including automated liquid handling technology to ensure the accuracy and precision needed for high-throughput DNA and RNA extraction and verification.
The integration of these services allows Hybrid GenConnect to provide customers with a sample renewal and extension process to maximize their samples for comprehensive research and development activities. Once samples are processed, aliquots of blood and/or DNA products can be retrieved and scheduled for transport to research testing sites through the company’s proprietary tracking and inventory management system, GenTrack®. This process ensures samples are removed, transported, processed and replaced to storage in a compliant, consistent and efficient fashion.
“The future of drug discovery is in personalized medicine and genomic-based therapies, which will require an ability to store and analyze large quantities of tissue and blood samples,” added Conrad. “As this trend continues, an increasing amount of pharma and biotech companies rely on our expertise in comprehensive sample management to ensure their valuable biological samples are managed in optimal conditions and not jeopardized by pre-analytical variabhttp://www.blogger.com/img/blank.gifles that can have a negative impact on sample integrity.”
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15oC to 27oC, bulk sample storage at 15oC to 27oC, walk-in cold sample storage -20oC to 5oC, ultra-low temperature storage -70C to -80C, and -190oC vapor phase liquid nitrogen. In addition, Hybrid GenConnect maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About Hybrid GenConnect Inc,.
For 23 years, Hybrid Medical eNotebook Inc Core Competency are Biotech Engineering, Software Engineers, and Enterprise Networking. At Hybrid Medical we pride ourselves on our Boutique Relationship with our Private Sector and Public Sector Clients. This methodology allows us to be able to offer our Clients “End to End” Solutions to their Enterprise Services. We have done extensive Research in Service Oriented Architecture (S.O.A) and Enterprise Service Bus (ESB) and we feel that our Strategies and your Strategies create valuable Synergies. Let's investigate the Possibilities for Synergies between our Company and yours.
HMA Inc we provide Network Services Contracts that include: design, installation and management of wide area networks and local area networks; enterprise server services that include anti-virus and content filters; BlackBerry support; patch support; technical helpdesk support including network hardware and software maintenance; desktop hardware/software installation and integration; application development; systems integration; Java/Oracle and legacy database development and maintenance; and citywide closed-circuit television services.>
HMA Inc comprehensive data protection strategy can save your company time. Our Process of backing up files, applications, databases, email and networked devicesis protected to ensure business continuity and compliance. When your business matures and grows, the volume of data increases and newer and more complex data retention requirements are introduced you are covered by hmnotebook.com Cloud Data Center (MCDC)™

Certify Electronic Health Records in Texas is in good hands

May 20, 2011 By Robert Graham --Houston Grand Hyatt ----Texas Medical Association Conference


Certify electronic health records in Texas is in good hands

certify electronic health record


Certification of EHRs is part of a broad initiative undertaken by Congress and President Obama under the Health Information Technology for Economic and Clinical Health (HITECH) Act,

$20 million in new technical support assistance to help critical access and rural hospital facilities convert from paper-based medical records to certified electronic health record (EHR) technology. Some 1,655 critical access and rural hospitals in 41 states and the nationwide Indian Country, headquartered in the
District of Columbia, stand to benefit from this assistance, which can help each of them qualify for substantial EHR incentive payments from Medicare and Medicaid


Certify electronic health record in Texas is in good hands
fresh off of winning Best of show at Texas Medical Assoc by
Hybrid Medical Integrated Health Care Solutions (IHCS)

IHCS Product DiagnoSYS™ answers the difficult questions that are asked when evaluating an organization's EMR needs.

IHCS DiagnoSYS™ will not completely change the way your organization runs. Instead, IHCS DiagnoSYS™ is flexible enough to fit into your existing workflow while improving, streamlining, and smoothing the rough edges in your work processes. IHCS DiagnoSYS™ incorporates a full-featured Business Process Management (BPM) engine that can accommodate any of your process needs such as rules-based routing, deadlines, and audit trails. Electronic patient scheduling and check-in improve efficiency. Electronic sign-off saves staff time and allows fast, accurate turnaround for the patient.

The product offering of IHCS DiagnoSYS™ includes an industry-leading document management system (DMS). A DMS allows the storage of most media including scanned or electronic documents, voice prints, and specialized images.

The design of IHCS DiagnoSYS™ allows for clinical content tailored to your special needs. IHCS DiagnoSYS™ supports the most common ways clinicians create charts including templates, free text typing, voice capture, scanning, and handheld device usage. No matter which method is preferred, IHCS DiagnoSYS™ allows you to work the way you want.

IHCS DiagnoSYS™ is a modularized application. With a modular design, you can add functionality as your needs grow. IHCS DiagnoSYS™ has scheduling, document management, human resource, auto reminder, EMR, billing, prescription, and referral modules. Some organizations might wish to add document imaging in the early phase, while waiting later to implement scheduling or EMR components. On the other hand, a modular approach may not work best for you and you may require full operation from the start. No matter what implementation approach you choose, IHCS DiagnoSYS™ will work for you. IHCS DiagnoSYS™ is designed to provide a return on investment for our customers via generating revenue, reducing inefficiencies, and improving patient care. Some of the benefits include:

Reduction of operating costs
Secured data storage and access
Accurate billing and coding through templates and rules based engine
Streamlined business processes
Staff, resource, and facility scheduling
Quality care to patients
HIPAA-compliant

IHCS DiagnoSYS™ powerfully streamlines the complete practice workflow. With its full suite of modules, it automates all the vital processes within a practice. It acts as a gateway that integrates staff, facilities, and resources across all processes. These processes include billing, scheduling, prescriptions, patient notes, treatment plans, and staffing to the insurance company.

Also in Texas News Drummond Group Inc. (DGI), Austin, Texas, were named today by the Office of the National Coordinator for Health Information Technology (ONC) as the first technology review bodies that have been authorized to test and certify
electronic health record (EHR) systems for compliance with the standards and certification criteria that were issued
by the U.S. Department of Health and Human Services

ONC-ATCB certifiers. EHR vendors can begin immediately to get their products certified.” said David Blumenthal, M.D., national
coordinator for Health Information Technology. This is a crucial step because it ensures that certified EHR products will be available
to support the achievement of the required meaningful use objectives, that these products will be aligned with one another on key standards, and that doctors and hospitals can invest with
confidence in these certified systems.”

Breast Cancer Let's look under the Hood

May 7,, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Breast Cancer Let's look under the Hood


Breast Cancer patients the structure and biological behavior of a cell is determined by the pattern of gene expression within that
cell. Each human cell contains approximately three billion
base pairs, which encode between 50 000 to 100 000
genes [1±3]. In any given cell only a small fraction of
these genes is being actively transcribed. Breast Cancer can be
regarded as a genetic disease occurring as a result of
progressive accumulation of genetic aberrations [4].
Neoplastic cells have numerous acquired genetic abnormalities
including aneuploidy, chromosomal rearrangements,
amplifications, deletions, gene rearrangements,
and loss or gain of function mutations.

Breast cancer is a disease in which certain cells in the breast
become abnormal and multiply without control or order to form a
tumor. The most common form of breast cancer begins in cells
lining the ducts that carry milk to the nipple (ductal cancer).
Other forms of breast cancer begin in the glands that produce
milk (lobular cancer) or in other parts of the breast

Tumors that begin at one site and then spread to other areas
of the body are called metastatic breast cancers.
Hereditary breast cancers tend to occur earlier in life than
noninherited (sporadic) cases and are more likely to involve both breast

Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid Medical breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.